medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-8-86-91medsovet-1312Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYДиацереин при лечении остеоартритаDiacerein the treatment of osteoarthritisАлексееваЛ. И.AlekseevaL. I.noemail@neicon.ruКашевароваН. Г.KashevarovaN. G.noemail@neicon.ruНаучно-исследовательский институт ревматологии им. В.А. НасоновойРоссияResearch Institute of Rheumatology named after V.A. NasonovaRussian Federation201630122016088691Copyright © Алексеева Л.И., Кашеварова Н.Г., 20162016Алексеева Л.И., Кашеварова Н.Г.Alekseeva L.I., Kashevarova N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1312

В статье обсуждаются возможности использования симптоматических препаратов замедленного действия в лечении остеоартрита (ОА). Представлен обзор клинических исследований эффективности и безопасности диацереина при различных формах ОА.

The article discusses the possibility of using symptomatic slow-acting drugs for the treatment of osteoarthritis (OA). There is a review of clinical studies evaluating the efficacy and safety of diacerein in different forms of OA.

остеоартритсимптоматические препараты замедленного действиядиацереинosteoarthritissymptomatic slow-acting drugsdiacereinReferencesLoeser RF, GoLdring SR, ScanzeLLo CR, GoLdring MB. Osteoarthritis - a disease of the joint as an organ. Arthritis Rheum, 2012, 64: 1697-707.Loeser RF, GoLdring SR, ScanzeLLo CR, GoLdring MB. Osteoarthritis - a disease of the joint as an organ. Arthritis Rheum, 2012, 64: 1697-707.Ovist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, KarsdaL MA. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res, 2008, 58(1): 1-7,Ovist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, KarsdaL MA. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res, 2008, 58(1): 1-7,Bruyere O, Cooper C, PeLLetier JP, Branco J, Luisa Brandi M, GuiLLemin F, et aL. An aLgorithm recommendation for the management of knee osteoarthritis in Europe and internationaLLy: A report from a task force of the European Society for CLinicaL and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014, 44(3): 253-63.Bruyere O, Cooper C, PeLLetier JP, Branco J, Luisa Brandi M, GuiLLemin F, et aL. An aLgorithm recommendation for the management of knee osteoarthritis in Europe and internationaLLy: A report from a task force of the European Society for CLinicaL and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014, 44(3): 253-63.MarteL-PeLLetier J and PeLLetier J-P. Effects of diacerein at the moLecuLar LeveL in the osteoar-thritis disease process. Ther. Adv. Musculoskel. Dis., 2010, 2(2): 95-104.MarteL-PeLLetier J and PeLLetier J-P. Effects of diacerein at the moLecuLar LeveL in the osteoar-thritis disease process. Ther. Adv. Musculoskel. Dis., 2010, 2(2): 95-104.MoLdovan F, PeLLetier JP, JoLicoeur FC, CLoutier JM, MarteL-PeLLetier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritic cartiLage. Osteoarthr Cartil, 2000, 8: 186-96.MoLdovan F, PeLLetier JP, JoLicoeur FC, CLoutier JM, MarteL-PeLLetier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritic cartiLage. Osteoarthr Cartil, 2000, 8: 186-96.MarteL-PeLLetier J, Mineau F, JoLicoeur FC, CLoutier JM, PeLLetier JP. In vitro effects of diacerhein and rhein on interLeukin 1 and tumor necrosis factor-aLpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol, 1998, 25(4): 753-62.MarteL-PeLLetier J, Mineau F, JoLicoeur FC, CLoutier JM, PeLLetier JP. In vitro effects of diacerhein and rhein on interLeukin 1 and tumor necrosis factor-aLpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol, 1998, 25(4): 753-62.PeLLetier JP, Mineau F, Ranger P, Tardif G, MarteL-PeLLetier J. The increased synthesis of inducibLe nitric oxide inhibits IL-1 rasynthesis by human articuLar chondrocytes: possibLe roLe in osteoarthritic cartiLage degradation. Osteoarthr Cartil, 1996, 4(1): 77-84.PeLLetier JP, Mineau F, Ranger P, Tardif G, MarteL-PeLLetier J. The increased synthesis of inducibLe nitric oxide inhibits IL-1 rasynthesis by human articuLar chondrocytes: possibLe roLe in osteoarthritic cartiLage degradation. Osteoarthr Cartil, 1996, 4(1): 77-84.Yaron M, Shirazi I, Yaron I. Anti-interLeukin-1 effects of diacerein and rhein in human osteo-arthritic synoviaL tissue and cartiLage cuLtures. Osteoarthr Cartil, 1999, 7(3): 272-80.Yaron M, Shirazi I, Yaron I. Anti-interLeukin-1 effects of diacerein and rhein in human osteo-arthritic synoviaL tissue and cartiLage cuLtures. Osteoarthr Cartil, 1999, 7(3): 272-80.Mendes AF, Caramona MM, de CarvaLho AP et aL. Diacerhein and Rhein prevent IL-1b-induced nucLear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B aLfa. Pharmacol Toxicol, 2002, 91: 22-8.Mendes AF, Caramona MM, de CarvaLho AP et aL. Diacerhein and Rhein prevent IL-1b-induced nucLear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B aLfa. Pharmacol Toxicol, 2002, 91: 22-8.Martin G, Bogdanowicz P, DomagaLa F, Ficheux H, PujoL JP. Rhein inhibits interLeukin-1beta-induced activation ofMEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cuLtured in hypoxia: a potentiaL mechanism for its disease-modifying effect in osteo-arthritis. Inflammation, 2003, 27(4): 233-46.Martin G, Bogdanowicz P, DomagaLa F, Ficheux H, PujoL JP. Rhein inhibits interLeukin-1beta-induced activation ofMEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cuLtured in hypoxia: a potentiaL mechanism for its disease-modifying effect in osteo-arthritis. Inflammation, 2003, 27(4): 233-46.Ferreira Mendes A, Caramona MM, de CarvaLho AP, Lopes MC. Diacerhein and rhein prevent interLeukin-1 beta-induced nucLear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-aLpha. Pharmacol Toxicol, 2002, 91(1): 22-8.Ferreira Mendes A, Caramona MM, de CarvaLho AP, Lopes MC. Diacerhein and rhein prevent interLeukin-1 beta-induced nucLear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-aLpha. Pharmacol Toxicol, 2002, 91(1): 22-8.FeLisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, GaLerra P et aL. StimuLating effect of diacerein on TGF beta 1 and beta 2 expression in articuLar chondrocytes cuLtured with and without interLeukin-1. Osteoarthr Cartil, 1999, 7(3): 255-64.FeLisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, GaLerra P et aL. StimuLating effect of diacerein on TGF beta 1 and beta 2 expression in articuLar chondrocytes cuLtured with and without interLeukin-1. Osteoarthr Cartil, 1999, 7(3): 255-64.Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articuLar chondrocytes in aLginate beads. Biochem Pharmacol, 2003, 65(3): 377-88.Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articuLar chondrocytes in aLginate beads. Biochem Pharmacol, 2003, 65(3): 377-88.Scho'ngen RN, Giannetti BM, Van de Leur E, Reinards R, GreiLing H. Effect of diacetyLrhein on the phagocytosis of poLymorphonucLear Leucocytes and its infLuence on the biosynthesis of hyaLuronate in synoviaL ceLLs. Arzneimittelforschun, 1988, 38(I)(5): 744-8.Scho'ngen RN, Giannetti BM, Van de Leur E, Reinards R, GreiLing H. Effect of diacetyLrhein on the phagocytosis of poLymorphonucLear Leucocytes and its infLuence on the biosynthesis of hyaLuronate in synoviaL ceLLs. Arzneimittelforschun, 1988, 38(I)(5): 744-8.PeLLetier JP, Lajeunesse D, RebouL P, Mineau F, Fernandes JC, Sabouret P et aL. Diacerein reduces the excess synthesis of bone remodeLing factors by human osteobLast ceLLs from osteoarthritic subchondraL bone. J Rheumatol, 2001, 28(4): 814-24.PeLLetier JP, Lajeunesse D, RebouL P, Mineau F, Fernandes JC, Sabouret P et aL. Diacerein reduces the excess synthesis of bone remodeLing factors by human osteobLast ceLLs from osteoarthritic subchondraL bone. J Rheumatol, 2001, 28(4): 814-24.PeLLetier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et aL. Efficacy and safety of diacerein in osteoarthritis of the knee: a doubLe-bLind, pLacebo-controLLed triaL. The Diacerein Study Group. Arthritis Rheum, 2000, 43(10): 2339-48.PeLLetier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et aL. Efficacy and safety of diacerein in osteoarthritis of the knee: a doubLe-bLind, pLacebo-controLLed triaL. The Diacerein Study Group. Arthritis Rheum, 2000, 43(10): 2339-48.RinteLen B, Neumann K, Leeb BF. A meta-anaLy-sis of controLLed cLinicaL studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006, 166(17): 1899-906. (Erratum in: ArchIntern Med. 2007;167(5):444).RinteLen B, Neumann K, Leeb BF. A meta-anaLy-sis of controLLed cLinicaL studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006, 166(17): 1899-906. (Erratum in: ArchIntern Med. 2007;167(5):444).FideLix TSA, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev, 2006 Jan 25, 1: CD005117.FideLix TSA, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev, 2006 Jan 25, 1: CD005117.BarteLs EM, BLiddaL H, Schondorff PK, ALtman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-anaLysis of randomized pLacebo-controLLed triaLs. Osteoarthr Cartil, 2010, 18(3): 289-96.BarteLs EM, BLiddaL H, Schondorff PK, ALtman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-anaLysis of randomized pLacebo-controLLed triaLs. Osteoarthr Cartil, 2010, 18(3): 289-96.Удовика М.И. Диацереин как препарат выбора в терапии остеоартроза коленных суставов с вторичным рецидивирущим синовитом. Научно-практическая ревматология, 2015, 53(6): 614-618.Удовика М.И. Диацереин как препарат выбора в терапии остеоартроза коленных суставов с вторичным рецидивирущим синовитом. Научно-практическая ревматология, 2015, 53(6): 614-618.Заиграева Н.К. Оценка эффектиности препарата Артрокер при остеоартрозе коленных суставов. Современная ревматология, 2013, 7(4): 23-5.Заиграева Н.К. Оценка эффектиности препарата Артрокер при остеоартрозе коленных суставов. Современная ревматология, 2013, 7(4): 23-5.PaveLka K, Bruye re O, Cooper C, Kanis JA, Burkhard FL, Maheu E, MarteL-PeLLetier J, Monfort J, PeLLetier J-P, Rene' R, Reginster J-Y. Diacerein: Benefits, Risks and PLace in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging, 2016, 33: 75-85. DOI 10.1007/s40266-016-0347-4PaveLka K, Bruye re O, Cooper C, Kanis JA, Burkhard FL, Maheu E, MarteL-PeLLetier J, Monfort J, PeLLetier J-P, Rene' R, Reginster J-Y. Diacerein: Benefits, Risks and PLace in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging, 2016, 33: 75-85. DOI 10.1007/s40266-016-0347-4Dougades M, Nguen M, Berdah L et aL. EvaLuation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-pLacebo-controLLed triaL. Arthr Rheum, 2001, 44(11): 2539-47,Dougades M, Nguen M, Berdah L et aL. EvaLuation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-pLacebo-controLLed triaL. Arthr Rheum, 2001, 44(11): 2539-47,Балабанова Р.М. Применение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный опыт). Современная ревматология, 2015, 9(3): 30-32.Балабанова Р.М. Применение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный опыт). Современная ревматология, 2015, 9(3): 30-32.Assessment report for diacerein containing medicinaL products. 28 August 2014 EMA/527347/2014.Assessment report for diacerein containing medicinaL products. 28 August 2014 EMA/527347/2014.PRAC recommends suspension of diacerein-containing medicines. Committee cites concerns over gastro-intestinaL side effects and Liver toxicity. 6 December 2013 EMA/679264/2013/rev.2.PRAC recommends suspension of diacerein-containing medicines. Committee cites concerns over gastro-intestinaL side effects and Liver toxicity. 6 December 2013 EMA/679264/2013/rev.2.Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhea in the eLderLy. Drugs Aging, 1998, 13(3): 245-53.Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhea in the eLderLy. Drugs Aging, 1998, 13(3): 245-53.Каратеев А.Е., Алексеева Л.И. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно-практическая ревматология, 2015, 53(2): 169-174.Каратеев А.Е., Алексеева Л.И. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно-практическая ревматология, 2015, 53(2): 169-174.Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечнососудистой коморбидностью и противопоказаниями к НПВП. Поликлиника, 2015, 5(1): 33-37.Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечнососудистой коморбидностью и противопоказаниями к НПВП. Поликлиника, 2015, 5(1): 33-37.

The authors declare that there are no conflicts of interest present.